FrancophonIA/ELRC3.0 huggingface dataset:
English: Physicians should exercise caution when considering the use of Riximyo in patients with a history of recurring or chronic infections or with underlying conditions which may further predispose patients to serious infection (see section 4.8).
Croatian: Liječnici trebaju biti oprezni ako razmatraju primjenu lijeka Riximyo u bolesnika s anamnezom rekurentnih ili kroničnih infekcija ili postojećim stanjima koje ih mogu dodatno predisponirati za ozbiljne infekcije (vidjeti dio 4.8).
English: Therefore vaccination with live virus vaccines is not recommended whilst on Riximyo or whilst peripherally B cell depleted.
Croatian: Stoga se ne preporučuje cijepljenje živim virusnim cjepivima za vrijeme primjene lijeka Riximyo odnosno dok je prisutna deplecija B-stanica u perifernoj krvi.
English: How to store Riximyo
Croatian: Kako čuvati lijek Riximyo
English: Riximyo maintenance therapy is indicated for the treatment of follicular lymphoma patients responding to induction therapy.
Croatian: Terapija održavanja lijekom Riximyo indicirana je u liječenju bolesnika oboljelih od folikularnog limfoma koji su odgovorili na uvodnu terapiju.
English: Pneumocystis jirovecii pneumonia (PCP) prophylaxis is recommended for patients with GPA/MPA or PV during and following Riximyo treatment, as appropriate according to local clinical practice guidelines.
Croatian: Pneumocystic jirovecii tijekom i nakon liječenja lijekom Riximyo, prema potrebi i u skladu s lokalnim smjernicama za kliničku praksu
English: The Patient educational leaflet about Riximyo contains the following key elements: - Detailed information on the risk of infections and PML - Information on the signs and symptoms of infections, especially PML, and the need to contact their doctor immediately if they experience any - The importance of sharing this information with their partner or caregiver - Information on the Patient Alert Card
Croatian: Informacijski letak za bolesnike o lijeku Riximyo sadrži sljedeće ključne elemente: - Detaljne informacije o riziku od infekcija i PML-a - Informacije o znakovima i simptomima infekcija, osobito PML-a, i napomenu da se odmah obrate svom liječniku ako primijete neki od njih
English: Granulomatosis with polyangiitis and microscopic polyangiitis Patients treated with Riximyo must be given the patient alert card with each infusion.
Croatian: Granulomatoza s poliangitisom i mikroskopski poliangitis Bolesnici koji se liječe lijekom Riximyo moraju kod svake infuzije dobiti karticu s upozorenjima za bolesnika.
English: If you have granulomatosis with polyangiitis, microscopic polyangiitis or pemphigus vulgaris also tell your doctor
Croatian: Imate li granulomatozu s poliangitisom, mikroskopski poliangitis ili obični pemfigus, obavijestite svog liječnika
English: What Riximyo is used for
Croatian: Što je Riximyo i za što se koristi Što je Riximyo
English: If you are not sure, talk to your doctor, pharmacist or nurse before you are given Riximyo.
Croatian: Ako niste sigurni, obratite se svom liječniku, ljekarniku ili medicinskoj sestri prije nego što počnete primjenjivati lijek Riximyo.
English: Since hypotension may occur during rituximab infusion, consideration should be given to withholding anti-hypertensive medicinal products 12 hours prior to the Riximyo infusion.
Croatian: Budući da tijekom infuzije rituksimaba može doći do hipotenzije, treba razmotriti mogućnost izostavljanja antihipertenzivnih lijekova 12 sati prije primjene infuzije lijeka Riximyo.
English: • If you are having Riximyo with chemotherapy
Croatian: • ako se liječite lijekom Riximyo u kombinaciji s kemoterapijom
English: The complete response rate after cycle 8 was 76.2% in the R-CHOP group and 62.4% in the CHOP group
Croatian: Nakon 24 mjeseca procjene ukupnog preživljenja iznosile su 68,2 % za R-CHOP skupinu, odnosno 57,4 % za CHOP skupinu.
English: The recommended dosage of Riximyo for induction of remission therapy of granulomatosis with polyangiitis and microscopic polyangiitis is 375 mg/m2 body surface area, administered as an intravenous infusion once weekly for 4 weeks (four infusions in total).
Croatian: Preporučena doza lijeka Riximyo za poticanje remisije granulomatoze s poliangitisom i mikroskopskog poliangitisa iznosi 375 mg/m2 tjelesne površine primijenjeno intravenskom infuzijom jedanput tjedno tijekom 4 tjedna (ukupno četiri infuzije).
English: Riximyo is used for the treatment of granulomatosis with polyangiitis (formerly called Wegener's granulomatosis) or microscopic polyangiitis, taken in combination with corticosteroids.
Croatian: Riximyo se u kombinaciji s kortikosteroidima primjenjuje za liječenje granulomatoze s poliangitisom (ranije se zvala Wegenerova granulomatoza) i mikroskopskog poliangitisa.
English: For CLL patients whose lymphocyte counts are > 25 x 109/L it is recommended to administer prednisone/prednisolone 100 mg intravenous shortly before infusion with Riximyo to decrease the rate and severity of acute infusion reactions and/or cytokine release syndrome.
Croatian: U bolesnika s KLL-om koji imaju broj limfocita > 25 × 109/l preporučuje se primjena prednizona/prednizolona u dozi od 100 mg intravenski neposredno prije infuzije lijeka Riximyo kako bi se smanjila stopa i težina akutne infuzijske reakcije i/ili sindroma otpuštanja citokina.
English: You should also tell them about your Riximyo treatment.
Croatian: Recite im i da se liječite lijekom Riximyo.
English: Riximyo is provided in sterile, preservative-free, non-pyrogenic, single use vials.
Croatian: Riximyo je dostupan u sterilnim, jednokratnim apirogenim bočicama, bez konzervansa.
English: Your doctor may prescribe Riximyo for the treatment of:
Croatian: Vam može propisati lijek Riximyo za liječenje sljedećih bolesti:
English: Since hypotension may occur during rituximab administration, consideration should be given to withholding anti-hypertensive medicinal product 12 hours prior to the Riximyo infusion.
Croatian: S obzirom da tijekom primjene rituksimaba može doći do hipotenzije, potrebno je razmotriti mogućnost izostavljanja antihipertenzivnog lijeka 12 sati prije davanja infuzije lijeka Riximyo.
English: Less frequently, some patients may experience pain at the infusion site, blisters, itching, sickness (nausea), tiredness, headache, breathing difficulties, blood pressure raised, wheezing, throat discomfort, tongue or throat swelling, itchy or runny nose, vomiting, flushing or palpitations, heart attack or low number of platelets.
Croatian: Rjeđe se u nekih bolesnika mogu pojaviti bol na mjestu infuzije, plikovi, svrbež, mučnina, umor, glavobolja, otežano disanje, povišen krvni tlak, piskanje pri disanju, nelagoda u grlu natečenost jezika ili grla,
English: Riximyo monotherapy is indicated for treatment of patients with stage III-IV follicular lymphoma who are chemoresistant or are in their second or subsequent relapse after chemotherapy.
Croatian: Monoterapija lijekom Riximyo indicirana je u liječenju bolesnika oboljelih od folikularnog limfoma stadija III-IV koji su rezistentni na kemoterapiju ili su u drugom odnosno sljedećem relapsu nakon kemoterapije.
English: It is recommended that immunoglobulin levels are determined prior to initiating treatment with Riximyo.
Croatian: Preporučuje se prije početka liječenja lijekom Riximyo odrediti razine imunoglobulina.
English: PATIENT ALERT CARD TEXT FOR NON-ONCOLOGY INDICATIONS Riximyo Alert Card for patients with non-oncology diseases
Croatian: Riximyo kartica s upozorenjima za bolesnike s neonkološkim bolestima
English: In patients with granulomatosis with polyangiitis (Wegener's) or microscopic polyangiitis in disease remission or pemphigus vulgaris, premedication with 100 mg intravenous methylprednisolone should be completed 30 minutes prior to Riximyo infusions to decrease the incidence and severity of infusion related reactions (IRRs).
Croatian: U bolesnika s granulomatozom s poliangitisom (Wegenerovom granulomatozom) ili mikroskopskim poliangitisom u remisiji ili s običnim pemfigusom treba primijeniti premedikaciju metilprednizolonom u dozi od 100 mg intravenski radi smanjenja incidencije i težine reakcija povezanih s infuzijom, a primjena mora završiti 30 minuta prije početka infuzije lijeka Riximyo.
English: The chemotherapy should be given after the Riximyo infusion.
Croatian: Kemoterapiju treba dati nakon infuzije lijeka Riximyo.
English: Rituximab was administered at a dosage of 375 mg/m2 during the first cycle one day prior to chemotherapy and at a dosage of 500 mg/m2 on day 1 of each subsequent treatment cycle.
Croatian: 375 mg/m2 u prvom ciklusu jedan dan prije kemoterapije i u dozi od 500 mg/m2 prvog dana svakog sljedećeg ciklusa.
English: All patients treated with Riximyo for rheumatoid arthritis, granulomatosis with polyangiitis, microscopic polyangiitis or pemphigus vulgaris must be given the patient alert card with each infusion.
Croatian: Svim bolesnicima s reumatoidnim artritisom, granulomatozom s poliangitisom, mikroskopskim poliangitisom ili običnim pemfigusom koji se liječe lijekom Riximyo potrebno je uz svaku infuziju dati karticu s upozorenjima za bolesnika.
English: • recurrence of a previous Hepatitis B infection c) If you are being treated for pemphigus vulgaris
Croatian: • povratak ranije hepatitis B infekcije c) Bolesnici koji se liječe od običnog pemfigusa
English: albumin, B symptoms, bulky disease, extranodal sites, bone marrow involvement), the risk ratios for event-free survival and overall survival (R-CHOP compared with CHOP) were less than 0.83 and 0.95 respectively.
Croatian: ekstranodalna sijela, zahvaćenost koštane srži) omjer hazarda za preživljenje bez događaja (R-CHOP u odnosu na CHOP) bio je manji od 0,83, a za ukupno preživljenje manji od 0,95.
English: Riximyo is indicated for the treatment of patients with moderate to severe pemphigus vulgaris (PV).
Croatian: Riximyo je indiciran za liječenje bolesnika s umjerenim do teškim oblikom običnog pemfigusa (PV).
English: Duration of response * Disease free survival (DFS)** Time to new CLL treatment
Croatian: Trajanje odgovora* Preživljenje bez bolesti (DFS)**
English: Riximyo 100 mg concentrate for solution for infusion Riximyo 500 mg concentrate for solution for infusion
Croatian: Riximyo 100 mg koncentrat za otopinu za infuziju Riximyo 500 mg koncentrat za otopinu za infuziju
English: Keep this medicine out of the sight and reach of children.
Croatian: Kako čuvati lijek Riximyo Lijek čuvajte izvan pogleda i dohvata djece.
English: The recommended dosage of Riximyo in combination with chemotherapy for previously untreated and relapsed/refractory patients is 375 mg/m2 body surface area administered on day 0 of the first treatment cycle followed by 500 mg/m2 body surface area administered on day 1 of each subsequent cycle for 6 cycles in total.
Croatian: Preporučena doza lijeka Riximyo u kombinaciji s kemoterapijom za prethodno neliječene bolesnike i bolesnike koji nisu odgovorili na liječenje ili su u relapsu iznosi 375 mg/m2 tjelesne površine primijenjeno nultog dana prvog ciklusa liječenja, nakon čega slijedi 500 mg/m2 tjelesne površine primijenjeno prvog dana svakog sljedećeg ciklusa, tijekom ukupno 6 ciklusa.
English: What you need to know before you are given Riximyo Do not take Riximyo if
Croatian: • što morate znati prije nego primite lijek Riximyo
English: Response rate and CR rates analysed using Chi-squared Test. *: only applicable to patients achieving a CR, nPR, PR; NR: not reached n.a. not applicable **: only applicable to patients achieving a CR;
Croatian: *: primjenjivo samo za bolesnike koji su postigli CR, nPR ili PR; ND: nije dostignuto; n.p.: nije primjenjivo **: primjenjivo samo za bolesnike koji su postigli CR
English: The recommended dosage of Riximyo for the treatment of pemphigus vulgaris is 1000 mg administered as an IV infusion followed two weeks later by a second 1000 mg IV infusion in combination with a tapering course of glucocorticoids.
Croatian: Preporučena doza lijeka Riximyo za liječenje običnog pemfigusa iznosi 1000 mg primijenjeno intravenskom infuzijom, a potom se nakon dva tjedna primjenjuje druga doza od 1000 mg intravenskom infuzijom u kombinaciji s glukokortikoidima, čija se doza postupno smanjuje.
English: When you are treated with Riximyo in combination with chemotherapy, you will receive Riximyo infusions on day 0 cycle 1 then day 1 of each cycle for 6 cycles in total.
Croatian: b) Bolesnici koji se liječe od kronične limfocitne leukemije Kada se liječite lijekom Riximyo u kombinaciji s kemoterapijom, primit ćete infuziju lijeka Riximyo nultog dana prvog ciklusa, a zatim prvog dana svakog sljedećeg ciklusa tijekom ukupno 6 ciklusa.
English: Very rare atrial fibrillation, heart failure, myocardial infarction
Croatian: Srčani poremećaji angina pektoris, fibrilacija atrija, zatajenje srca, infarkt miokarda undulacija atrija
English: Hepatitis B virus (HBV) screening should be performed in all patients before initiation of treatment with Riximyo.
Croatian: Sve bolesnike mora se prije početka liječenja lijekom Riximyo testirati na virus hepatitisa B (HBV).
English: Table 10b First-line treatment of chronic lymphocytic leukaemia Hazard ratios of progression-free survival according to Binet stage (ITT) - 48.1 months median observation time
Croatian: Omjeri hazarda za preživljenje bez progresije bolesti prema Binetovom stadiju (ITT populacija) - medijan vremena promatranja je 48,1 mjesec
English: The acute respiratory failure may be accompanied by events such as pulmonary interstitial infiltration or oedema,
Croatian: Akutno zatajenje dišnog sustava mogu pratiti poremećaji kao što su infiltracija plućnog intersticija ili edem pluća, koji su vidljivi na radiografskoj snimci grudnog koša.
English: Chemical and physical stability of Riximyo diluted in 5% glucose solution has been demonstrated for 24 hours at 2°C - 8°C and subsequently 12 hours at room temperature (≤25°C).
Croatian: • Nakon aseptičkog razrjeđivanja u otopini glukoze: Dokazana je kemijska i fizička stabilnost lijeka Riximyo razrijeđenog u 5 %-tnoj otopini glukoze tijekom 24 sata na temperaturi od 2 °C do 8 °C te potom 12 sati na sobnoj temperaturi (≤ 25°C).
English: • swelling of the stomach.
Croatian: • oticanje trbuha
English: The recommended dose of Riximyo used as a maintenance treatment for patients with previously untreated follicular lymphoma who have responded to induction treatment is: 375 mg/m2 body surface area once every 2 months (starting 2 months after the last dose of induction therapy) until disease progression or for a maximum period of two years (12 infusions in total).
Croatian: Preporučena doza lijeka Riximyo u terapiji održavanja u bolesnika s prethodno neliječenim folikularnim limfomom koji su odgovorili na uvodno liječenje iznosi 375 mg/m2 površine tijela jedanput svaka 2 mjeseca (počevši 2 mjeseca nakon zadnje doze uvodne terapije) do progresije bolesti ili najdulje dvije godine (ukupno 12 infuzija).
English: Riximyo 100 mg concentrate for solution for infusion Each 10 mL vial contains 100 mg of rituximab.
Croatian: Riximyo 100 mg koncentrat za otopinu za infuziju Jedna bočica od 10 ml sadrži 100 mg rituksimaba (rituximabum).
English: Decreased IgG levels4
Croatian: snižene razine IgG
English: Riximyo is indicated for the treatment of patients with CD20 positive diffuse large B cell non-Hodgkin's lymphoma in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy.
Croatian: Riximyo je u kombinaciji s CHOP kemoterapijom (ciklofosfamid, doksorubicin, vinkristin, prednizolon) indiciran u liječenju bolesnika s CD20 pozitivnim difuznim ne-Hodgkinovim limfomom velikih B-stanica.
English: c) Granulomatosis with polyangiitis or microscopic polyangiitis
Croatian: c) granulomatoze s poliangitisom ili mikroskopskog poliangitisa
English: The study showed statistically significant results of rituximab and low-dose prednisone over standarddose prednisone in achieving CRoff ≥ 2 months at month 24 in PV patients (see Table 14).
Croatian: U 24. mjesecu ispitivanja kombinacija rituksimaba i niske doze prednizona ostvarila je statistički značajne rezultate u odnosu na standardnu dozu prednizona s obzirom na postizanje potpune remisije bez primjene kortikosteroida tijekom ≥ 2 mjeseca u bolesnika s PV-om (vidjeti Tablicu 14).
English: Progression-free survival (PFS) Number of patients
Croatian: Preživljenje bez progresije bolesti (PFS)
English: Riximyo 500 mg concentrate for solution for infusion Each 50 mL vial contains 500 mg of rituximab.
Croatian: Riximyo 500 mg koncentrat za otopinu za infuziju Jedna bočica od 50 ml sadrži 500 mg rituksimaba (rituximabum).
English: • Riximyo will be given to you once a week for 4 weeks.
Croatian: • ako se liječite samo lijekom Riximyo Lijek Riximyo primat ćete jedanput na tjedan tijekom 4 tjedna.
English: Sepsis, +pneumonia, +febrile infection, +herpes zoster, +respiratory tract infection, fungal infections, infections of unknown
Croatian: Infekcije i infestacije bakterijske infekcije, virusne infekcije, +bronhitis sepsa, +upala pluća, +febrilna infekcija, +herpes zoster, +infekcija dišnog sustava,
English: Immunoglobulins - IgM), chemical disturbances in the blood caused by break-down of dying cancer cells
Croatian: • kratkotrajno povišenje količine nekih vrsta protutijela u krvi (imunoglobulina - IgM), kemijski poremećaji krvi uzrokovani raspadanjem umirućih stanica raka • oštećenje živaca u rukama i nogama, paraliza lica
English: This should be followed by oral prednisone 1 mg/kg/day (not to exceed 80 mg/day, and tapered as rapidly as possible based on clinical need) during and after the 4 week induction course of Riximyo treatment.
Croatian: Nakon toga, treba tijekom i nakon 4tjednog uvodnog liječenja lijekom Riximyo peroralno davati prednizon u dozi od 1 mg/kg na dan (ne više od 80 mg na dan i što brže postupno smanjivati dozu, ovisno o kliničkoj potrebi).
English: Skin and Subcutaneous Tissue Disorders
Croatian: Poremećaji kože i potkožnog tkiva akne
English: Table 13 Complete remission at 6-months by disease status Rituximab Cyclophosphamide Difference (CI 95%)
Croatian: Tablica 13 Potpuna remisija nakon 6 mjeseci prema statusu bolesti Rituksimab
English: Your doctor may decide to treat you longer with Riximyo (up to 5 years), depending on how you respond to the medicine.
Croatian: Ovisno o tome kako reagirate na lijek, liječnik će Vam možda produljiti liječenje lijekom Riximyo (do 5 godina).
English: During rituximab maintenance treatment for up to 2 years, leucopenia (5% vs. 2%, grade 3/4) and neutropenia (10% vs. 4%, grade 3/4) were reported at a higher incidence when compared to observation.
Croatian: stupanj 3/4) i neutropenija (10 % u odnosu na 4 %, stupanj 3/4) su prijavljene učestalije nego u opservacijskoj skupini.
English: Premedication consisting of an anti-pyretic and an antihistaminic, e.g. paracetamol and diphenhydramine, should always be given before each administration of Riximyo.
Croatian: Prije svake primjene lijeka Riximyo uvijek treba primijeniti premedikaciju koja obuhvaća antipiretik i antihistaminik, npr. paracetamol i difenhidramin.
English: The recommended dose of Riximyo monotherapy used as induction treatment for adult patients with stage III-IV follicular lymphoma who are chemoresistant or are in their second or subsequent relapse after chemotherapy is: 375 mg/m2 body surface area, administered as an intravenous infusion once weekly for four weeks.
Croatian: • Relapsirajući/refraktorni folikularni limfom Preporučena doza lijeka Riximyo u monoterapiji kod početnog liječenja odraslih bolesnika oboljelih od folikularnog limfoma stadija III-IV koji su rezistentni na kemoterapiju ili su u drugom odnosno sljedećem relapsu nakon kemoterapije iznosi 375 mg/m2 površine tijela, a primjenjuje se u obliku intravenske infuzije jedanput tjedno tijekom četiri tjedna.
English: The recommended dose of Riximyo used as a maintenance treatment for patients with relapsed/refractory follicular lymphoma who have responded to induction treatment is: 375 mg/m2 body surface area once every 3 months (starting 3 months after the last dose of induction therapy) until disease progression or for a maximum period of two years (8 infusions in total).
Croatian: • Relapsirajući/refraktorni folikularni limfom Preporučena doza lijeka Riximyo u terapiji održavanja u bolesnika s relapsirajućim/refraktornim folikularnim limfomom koji su odgovorili na uvodno liječenje iznosi 375 mg/m2 površine tijela jedanput svaka 3 mjeseca (počevši 3 mjeseca nakon zadnje doze uvodne terapije) do progresije bolesti ili najdulje dvije godine (ukupno 8 infuzija).
English: Patients in both arms received 1,000 mg of pulse intravenous methylprednisolone (or another equivalent-dose glucocorticoid) per day for 1 to 3 days, followed by oral prednisone (1 mg/kg/day, not exceeding 80 mg/day).
Croatian: Bolesnici u obje skupine su tijekom 1 do 3 dana primali pulsnu intravensku terapiju metilprednizolonom u dozi od 1000 mg na dan (ili drugi glukokortikoid u ekvivalentnoj dozi),
English: Also do not breast-feed for 12 months after your last treatment with Riximyo.
Croatian: Ne smijete dojiti dijete tijekom liječenja lijekom Riximyo i još 12 mjeseci nakon posljednje primjene lijeka jer se Riximyo može izlučiti u majčino mlijeko.
English: How Riximyo is given How it is given
Croatian: Kako se primjenjuje lijek Riximyo Kako se Riximyo primjenjuje
English: Riximyo 500 mg concentrate for solution for infusion rituximab
Croatian: Riximyo 500 mg koncentrat za otopinu za infuziju Rituximabum (rituksimab)
English: Measure blood neutrophils prior to each course of Riximyo, and regularly up to 6-months after cessation of treatment, and upon signs or symptoms of infection (see section 4.8).
Croatian: 6 mjeseci nakon prestanka liječenja te po pojavi znakova ili simptoma infekcije (vidjeti dio 4.8).
English: Riximyo 100 mg concentrate for solution for infusion rituximab
Croatian: Riximyo 100 mg koncentrat za otopinu za infuziju Rituximabum (rituksimab)
English: Riximyo 100 mg sterile concentrate rituximab
Croatian: Riximyo 100 mg sterilni koncentrat Rituximabum (rituksimab)
English: The Patient Alert Card for Riximyo contains the following key elements: - The need to carry the card at all times and to show the card to all treating health care professionals - Warning on the risk of infections and PML, including the symptoms - The need for patients to contact their health care professional if symptoms occur
Croatian: Kartica s upozorenjima za bolesnika za lijek Riximyo sadrži sljedeće ključne elemente: - Karticu uvijek treba nositi sa sobom i pokazati je svim zdravstvenim radnicima koji bolesnika liječe
English: Riximyo 500 mg sterile concentrate rituximab
Croatian: Riximyo 500 mg sterilni koncentrat Rituximabum (rituksimab)
English: The cumulative incidence rate curves showed that time to first major relapse was longer in patients with rituximab starting from month 2 and was maintained up to month 28 (Figure 1).
Croatian: Krivulje kumulativne stope incidencije pokazuju dulje vrijeme do prvog teškog relapsa u bolesnika liječenih rituksimabom.
English: You must also do this for 12 months after your last treatment with Riximyo.
Croatian: Morate to činiti i još 12 mjeseci nakon posljednje primjene lijeka
English: The recommended dose of Riximyo in combination with chemotherapy for induction treatment of previously untreated or relapsed/ refractory patients with follicular lymphoma is: 375 mg/m2 body surface area per cycle, for up to 8 cycles.
Croatian: Preporučena doza lijeka Riximyo u kombinaciji s kemoterapijom za uvodno liječenje bolesnika s prethodno neliječenim ili relapsirajućim/refraktornim folikularnim limfomom iznosi 375 mg/m2
English: Some vaccines should not be given at the same time as Riximyo or in the months after you receive Riximyo.
Croatian: Riximyo ili nekoliko mjeseci nakon liječenja lijekom Riximyo.
English: Riximyo is indicated for the treatment of previously untreated patients with stage III-IV follicular lymphoma in combination with chemotherapy.
Croatian: Riximyo je u kombinaciji s kemoterapijom indiciran u liječenju bolesnika oboljelih od folikularnog limfoma stadija III-IV koji prethodno nisu liječeni.